Increased insulin-like growth factor-1 in relation to cardiovascular function in polycystic ovary syndrome: friend or foe?

References

• Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181–91
   Google Scholar
• Adashi EY. Intraovarian regulation: the proposed role of insulin-like growth factors. Ann NY Acad Sci 1993;687:10–12
   PubMed Web of Science ®Google Scholar
• Giordano G, Barreca A, Minuto F. Growth factors in the ovary. J Endocrinol Invest 1992;15:689–707
   PubMed Web of Science ®Google Scholar
• Garzo VG, Dorrington JH. Aromatase activity in human granulosa cells during follicular development and the modulation by follicle-stimulating hormone and insulin. Am J Obstet Gynecol 1984;148:657–62
   PubMed Web of Science ®Google Scholar
• Suikkari AM, Koivisto VA, Rutanen EM, et al. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988;66:266–72
   PubMed Web of Science ®Google Scholar
• Homburg R, Pariente C, Lunenfeld B, Jacobs HS. The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome. Hum Reprod 1992;7:1379–83
   PubMed Web of Science ®Google Scholar
• Suikkari AM, Jalkanen J, Koistinen R, et al. Human granulosa cells synthesize low molecular weight insulin-like growth factor-binding protein. Endocrinology 1989;124:1088–90
   PubMed Web of Science ®Google Scholar
• Boquist S, Ruotolo G, Skoglund-Andersson C, et al. Correlation of serum IGF-I and IGFBP-1 and-3 to cardiovascular risk indicators and early carotid atherosclerosis in healthy middle-aged men. Clin Endocrinol (Oxf) 2008;68:51–8
   PubMed Web of Science ®Google Scholar
• Schneider HJ, Klotsche J, Saller B, et al. Associations of age-dependent IGF-I SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6773 primary care patients. Eur J Endocrinol 2008;158:153–61
   PubMed Web of Science ®Google Scholar
• Fischer F, Schulte H, Mohan S, et al. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease. Clin Endocrinol (Oxf) 2004;61:595–602
   PubMed Web of Science ®Google Scholar
• Van Bunderen CC, van Nieuwpoort IC, van Schoor NM, et al. The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study. J Clin Endocrinol Metab 2010;95:4616–24
   PubMed Web of Science ®Google Scholar
• Andreassen M, Raymond I, Kistorp C, et al. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol 2009;160:25–31
   PubMed Web of Science ®Google Scholar
• Al-Obaidi MK, Hon JK, Stubbs PJ, et al. Plasma insulin-like growth factor-1 elevated in mild-to-moderate but not severe heart failure. Am Heart J 2001;142:E10
   PubMedGoogle Scholar
• Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: a review of atherosclerosis and restenosis. Circ Res 2000;86:125–30
   PubMed Web of Science ®Google Scholar
• Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004;89:114–20
   PubMed Web of Science ®Google Scholar
• Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol 1996;77:200–2
   PubMed Web of Science ®Google Scholar
• McKeigue P. Cardiovascular disease and diabetes in women with polycystic ovary syndrome. Baillieres Clin Endocrinol Metab 1996;10:311–18
   PubMed Web of Science ®Google Scholar
• Boomsma CM, Fauser BCJM, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med 2008;26:72–84
   PubMed Web of Science ®Google Scholar
• Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:3299–306
   PubMed Web of Science ®Google Scholar
• Shah KN, Patel SS. Phosphatidylinositide-3 kinase: a newer molecular target in metabolic and hormonal pathway of polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2014;122:261–7
   PubMed Web of Science ®Google Scholar
• Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril 2003;80:255–8
   PubMed Web of Science ®Google Scholar
• Kulshreshtha B, Ganie MA, Praveen EP, et al. Insulin response to oral glucose in healthy, lean young women and patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:637–43
   PubMed Web of Science ®Google Scholar
• Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107–11
   PubMed Web of Science ®Google Scholar
• Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 1990;32:213–20
   PubMed Web of Science ®Google Scholar
• Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health—National Heart, Lung, and Blood Institute Sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008;93:1276–84
   PubMed Web of Science ®Google Scholar
• Moran LJ, Pasquali R, Teede HJ, et al. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 2009;92:1966–82
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006;113:1148–59
   PubMed Web of Science ®Google Scholar
• Marx TL, Mehta AE. Polycystic ovary syndrome: pathogenesis and treatment over the short and long term. Cleve Clin J Med 2003;70:31–3, 36–41, 45
   PubMed Web of Science ®Google Scholar
• Nestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol 1997;15:111–22
   PubMedGoogle Scholar
• Ciaraldi TP, el-Roeiy A, Madar Z, et al. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992;75:577–83
   PubMed Web of Science ®Google Scholar
• Jakubowicz D, Wainstein J, Homburg R. The link between polycystic ovarian syndrome and type 2 diabetes: preventive and therapeutic approach in Israel. Isr Med Assoc J 2012;14:442–7
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–6
   PubMed Web of Science ®Google Scholar
• Mannerås-Holm L, Leonhardt H, Kullberg J, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 2011;96:E304–11
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998;83:2001–5
   PubMed Web of Science ®Google Scholar
• Baillargeon J-P, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82:893–902
   PubMed Web of Science ®Google Scholar
• Hussain MA, Schmitz O, Mengel A, et al. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 1993;92:2249–56
   PubMed Web of Science ®Google Scholar
• Acerini CL, Patton CM, Savage MO, et al. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997;350:1199–204
   PubMed Web of Science ®Google Scholar
• Yakar S, Liu JL, Fernandez AM, et al. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001;50:1110–18
   PubMed Web of Science ®Google Scholar
• Sandhu MS, Heald AH, Gibson JM, et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002;359:1740–5
   PubMed Web of Science ®Google Scholar
• D’Ercole AJ, Applewhite GT, Underwood LE. Evidence that somatomedin is synthesized by multiple tissues in the fetus. Dev Biol 1980;75:315–28
   PubMed Web of Science ®Google Scholar
• Mauras N. Growth hormone, IGF-I and growth. New views of old concepts. Modern endocrinology and diabetes series, volume 4 By Thomas J. Merimee and Zvi Laron. London, Freund, 1996, $130 (266 pages), ISBN 965-294-092-5. Trends Endocrinol Metab 1997;8:256–7
   Google Scholar
• Nilsson A, Isgaard J, Lindahl A, et al. Regulation by growth hormone of number of chondrocytes containing IGF-I in rat growth plate. Science 1986;233:571–4
   PubMed Web of Science ®Google Scholar
• Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 1999;253:1–6
   PubMed Web of Science ®Google Scholar
• Zapf J, Froesch E. Insulin-like growth factor I actions on somatic growth. In: Kostyo J, ed. Handbook of physiology. Philadelphia: American Physiological Society; 1999: 663–99( 5pp)
   Google Scholar
• Blundell TL, Humbel RE. Hormone families: pancreatic hormones and homologous growth factors. Nature 1980;287:781–7
   PubMed Web of Science ®Google Scholar
• Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978;253:2769–76
   PubMed Web of Science ®Google Scholar
• Roberts CT, Rosenfeld RG. The IGF system molecular biology, physiology, and clinical applications [Internet]. Totowa (NJ): Humana Press; 1999. Available from: http://books.google.com/books?id=f-9qAAAAMAAJ [last accessed 9 Dec 2014]
   Google Scholar
• Seino S, Seino M, Nishi S, Bell GI. Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci USA 1989;86:114–18
   PubMed Web of Science ®Google Scholar
• Bondy CA, Werner H, Roberts CT, LeRoith D. Cellular pattern of insulin-like growth factor-I (IGF-I) and type I IGF receptor gene expression in early organogenesis: comparison with IGF-II gene expression. Mol Endocrinol 1990;4:1386–98
   PubMed Web of Science ®Google Scholar
• Kato H, Faria TN, Stannard B, et al. Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action. Mol Endocrinol 1994;8:40–50
   PubMed Web of Science ®Google Scholar
• LeRoith D, Werner H, Beitner-Johnson D, Roberts CT. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;16:143–63
   PubMed Web of Science ®Google Scholar
• Adashi EY, Resnick CE, D’Ercole AJ, et al. Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function. Endocr Rev 1985;6:400–20
   PubMed Web of Science ®Google Scholar
• Pauli JM, Raja-Khan N, Wu X, Legro RS. Current perspectives of insulin resistance and polycystic ovary syndrome. Diabet Med 2011;28:1445–54
   PubMed Web of Science ®Google Scholar
• Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994;79:872–8
   PubMed Web of Science ®Google Scholar
• Thierry van Dessel HJ, Lee PD, Faessen G, et al. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84:3030–5
   PubMed Web of Science ®Google Scholar
• Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997;18:801–31
   PubMed Web of Science ®Google Scholar
• Conway GS, Jacobs HS, Holly JM, Wass JA. Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1990;33:593–603
   PubMed Web of Science ®Google Scholar
• Iwashita M, Mimuro T, Watanabe M, et al. Plasma levels of insulin-like growth factor-I and its binding protein in polycystic ovary syndrome. Horm Res 1990;33:21–6
   PubMed Web of Science ®Google Scholar
• Erickson GF, Magoffin DA, Cragun JR, Chang RJ. The effects of insulin and insulin-like growth factors-I and-II on estradiol production by granulosa cells of polycystic ovaries. J Clin Endocrinol Metab 1990;70:894–902
   PubMed Web of Science ®Google Scholar
• Cibula D, Cífková R, Fanta M, et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15:785–9
   PubMed Web of Science ®Google Scholar
• Wang HS, Chard T. IGFs and IGF-binding proteins in the regulation of human ovarian and endometrial function. J Endocrinol 1999;161:1–13
   PubMed Web of Science ®Google Scholar
• Bloch CA, Clemons P, Sperling MA. Puberty decreases insulin sensitivity. J Pediatr 1987;110:481–7
   PubMed Web of Science ®Google Scholar
• Smith CP, Archibald HR, Thomas JM, et al. Basal and stimulated insulin levels rise with advancing puberty. Clin Endocrinol (Oxf) 1988;28:7–14
   PubMed Web of Science ®Google Scholar
• Nobels F, Dewailly D. Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor I hypothesis. Fertil Steril 1992;58:655–66
   PubMed Web of Science ®Google Scholar
• Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989–93
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Roldán B, Barrio R, et al. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2000;85:4182–7
   PubMed Web of Science ®Google Scholar
• Elting MW, Korsen TJ, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 2001;16:556–60
   PubMed Web of Science ®Google Scholar
• Kelly CJG, Speirs A, Gould GW, et al. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:742–6
   PubMed Web of Science ®Google Scholar
• Grant MB, Wargovich TJ, Ellis EA, et al. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Circulation 1994;89:1511–17
   PubMed Web of Science ®Google Scholar
• Mathews LS, Norstedt G, Palmiter RD. Regulation of insulin-like growth factor I gene expression by growth hormone. Proc Natl Acad Sci USA 1986;83:9343–7
   PubMed Web of Science ®Google Scholar
• Wahlander H, Isgaard J, Jennische E, Friberg P. Left ventricular insulin-like growth factor I increases in early renal hypertension. Hypertension 1992;19:25–32
   PubMed Web of Science ®Google Scholar
• Engelmann GL, Boehm KD, Haskell JF, et al. Insulin-like growth factors and neonatal cardiomyocyte development: ventricular gene expression and membrane receptor variations in normotensive and hypertensive rats. Mol Cell Endocrinol 1989;63:1–14
   PubMed Web of Science ®Google Scholar
• Hutter R, Sauter BV, Reis ED, et al. Decreased reendothelialization and increased neointima formation with endostatin overexpression in a mouse model of arterial injury. Circulation 2003;107:1658–63
   PubMed Web of Science ®Google Scholar
• Donohue TJ, Dworkin LD, Lango MN, et al. Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. Circulation 1994;89:799–809
   PubMed Web of Science ®Google Scholar
• Liu JP, Baker J, Perkins AS, et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59–72
   PubMed Web of Science ®Google Scholar
• Frystyk J, Ledet T, Møller N, et al. Cardiovascular disease and insulin-like growth factor I. Circulation 2002;106:893–5
   PubMed Web of Science ®Google Scholar
• Janssen JA. MJL, Lamberts SWJ. The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol 2002;146:467–77
   PubMed Web of Science ®Google Scholar
• Ciaraldi TP, Carter L, Rehman N, et al. Insulin and insulin-like growth factor-1 action on human skeletal muscle: preferential effects of insulin-like growth factor-1 in type 2 diabetic subjects. Metab Clin Exp 2002;51:1171–9
   PubMed Web of Science ®Google Scholar
• Clemmons DR, Moses AC, McKay MJ, et al. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 2000;85:1518–24
   PubMed Web of Science ®Google Scholar
• Seibel SA, Chou KH, Capp E, et al. Effect of metformin on IGF-1 and IGFBP-1 levels in obese patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2008;138:122–4
   PubMed Web of Science ®Google Scholar
• Schini-Kerth VB. Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. J Endocrinol Invest 1999;22:82–8
   PubMedGoogle Scholar
• Conti E, Andreotti F, Sestito A, et al. Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries. Am J Cardiol 2002;89:973–5
   PubMed Web of Science ®Google Scholar
• Oltman CL, Kane NL, Gutterman DD, et al. Mechanism of coronary vasodilation to insulin and insulin-like growth factor I is dependent on vessel size. Am J Physiol Endocrinol Metab 2000;279:E176–81
   PubMed Web of Science ®Google Scholar
• Spies M, Nesic O, Barrow RE, et al. Liposomal IGF-1 gene transfer modulates pro-and anti-inflammatory cytokine mRNA expression in the burn wound. Gene Ther 2001;8:1409–15
   PubMed Web of Science ®Google Scholar
• Izhar U, Hasdai D, Richardson DM, et al. Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro. Coron Artery Dis 2000;11:69–76
   PubMed Web of Science ®Google Scholar
• Galderisi M, Caso P, Cicala S, et al. Positive association between circulating free insulin-like growth factor-1 levels and coronary flow reserve in arterial systemic hypertension. Am J Hypertens 2002;15:766–72
   PubMed Web of Science ®Google Scholar
• Haylor J, Singh I, el Nahas AM. Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I. Kidney Int 1991;39:333–5
   PubMed Web of Science ®Google Scholar
• Conti E, Andreotti F, Sciahbasi A, et al. Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. J Am Coll Cardiol 2001;38:26–32
   PubMed Web of Science ®Google Scholar
• Van den Beld AW, Bots ML, Janssen JA. MLL, et al. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 2003;157:25–31
   PubMed Web of Science ®Google Scholar
• Welch S, Plank D, Witt S, et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ Res 2002;90:641–8
   PubMed Web of Science ®Google Scholar